EFNS guidelines on disease‐specific CSF investigations

Deisenhammer, Florian; Egg, R.; Giovannoni, Gavin; Hemmer, Bernhard; Petzold, Axel; Sellebjerg, Finn; Teunissen, Charlotte E.; Tumani, Hayrettin

doi:10.1111/j.1468-1331.2009.02595.x

Cited by 74 publications

(53 citation statements)

References 250 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…9 During axonal damage, neurofilaments are released into the extracellular fluid and thus measurement of neurofilament levels in body fluids may indicate the extent of axonal damage within the CNS not only in MS but also in other neurodegenerative diseases. 3 Evidence for increased NfL and NfH levels in MS comes from several studies, as we will elaborate below. Recent reports provide evidence that the assessment of neurofilament levels may also enable monitoring of treatment efficacy or neurotoxic side effects.…”

Section: Introductionmentioning

confidence: 99%

“…CSF oligoclonal IgG bands and IgG index have proven diagnostic utility. 3 However, there is a lack of biomarkers for monitoring or predicting disease progression for use in clinical practice involving MS. 4,5 The cause of disease progression is axonal loss which is an irreversible process. 1,6 Thus, biomarkers reflecting axonal loss could be a valuable tool for predicting disease progression.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Neurofilaments as biomarkers in multiple sclerosis

2012

View full text Add to dashboard Cite

Neurodegeneration is the correlate of disease progression in multiple sclerosis (MS) and thus biological biomarkers that sensitively reflect this process are much needed. Neurofilament protein subunits are potential cerebrospinal fluid (CSF) biomarkers for disease progression in MS. We argue that the neurofilament light subunit can reflect acute axonal damage mediated by inflammatory mechanisms and can imply prognostic value for conversion from clinically isolated syndrome (CIS) to definite MS. The neurofilament heavy subunit may rather reflect chronic irreversible damage and has prognostic value for disease progression or disability. The neurofilament intermediate subunit has not yet been studied. Recent studies showing higher neurofilament light or heavy subunit levels to be altered upon treatment regimes indicate their potential clinical value in monitoring treatment or side effects. Future studies should be aimed at the optimisation, standardisation and interlaboratory implementation of the assays and address the predictive value of these biomarkers.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Neurofilaments as biomarkers in multiple sclerosis

2012

View full text Add to dashboard Cite

show abstract

“…However, the positive results have also been reported in other dementias and encephalopathies, infections and cerebrovascular diseases and metastases (Deisenhammer et al 2009 ). Other brain-derived proteins have also been considered as diagnostic markers for CJD.…”

Section: Csf Immunological Markersmentioning

confidence: 90%

Chronic Infectious Inflammatory Diseases of the Central Nervous System

Taba

Lutsar

2015

Cerebrospinal Fluid in Clinical Neurology

View full text Add to dashboard Cite

“…headache, Bell's palsy). They had normal MMSE and ACE-R-CZ scores and a normal CSF triplet (t-tau, p-tau, Abeta proteins) based on cut-offs established in our and other previous studies 24,28,32,33 . These patients underwent a lumbar puncture as part of a routine diagnostic work-up.…”

Section: Participantsmentioning

confidence: 99%

Neurofilaments and tau proteins in cerebrospinal fluid and serum in dementias and neuroinflammation

Fialová¹,

Bartoš²,

Švarcová³

2017

BIOMED PAP

View full text Add to dashboard Cite

Aims. The aim of this study was to evaluate the diagnostic potential of cerebrospinal fluid (CSF) and serum levels of neurocytoskeletal proteins and their ratios for the diagnosis of dementias and to assess the differences in neurocytoskeletal proteins between neurodegeneration and neuroinflammation. Methods. CSF and serum levels of neurofilament light subunits (NFL) and neurofilament heavy subunits (NFH) as well as CSF levels of total tau (t-tau) and phosphorylated tau (p-tau) proteins were determined using ELISA in 20 Alzheimer's disease patients (AD group), 13 patients with other dementias (OD group), 17 patients with inflammatory aseptic neuro-infections (IP), and 20 aged-matched cognitively normal elderly persons (NC group). Results. The ratio CSF p-tau/t-tau was significantly higher in the NC group than that in the AD or OD groups (P<0.0005 for each group). The CSF NFH/p-tau and CSF NFL/p-tau ratios were significantly lower in AD patients than OD patients (P≤0.003). Serum and CSF NFL and CSF NFH levels were significantly higher in OD patients than AD patients (P≤0.03).The lowest values of the CSF NFL/NFH ratio were found in the IP group and they significantly differed from those in normal controls (P<0.0001) and any dementia group (IP vs. AD P<0.0001; IP vs. OD P=0.03). Conclusion. CSF tau proteins and their index differentiated between AD or OD patients and cognitively normal subjects, while CSF levels of neurofilaments expressed as their index seem to contribute to the discrimination between patients with neuroinflammation and normal controls or AD patients.

show abstract

EFNS guidelines on disease‐specific CSF investigations

Cited by 74 publications

References 250 publications

Neurofilaments as biomarkers in multiple sclerosis

Neurofilaments as biomarkers in multiple sclerosis

Chronic Infectious Inflammatory Diseases of the Central Nervous System

Neurofilaments and tau proteins in cerebrospinal fluid and serum in dementias and neuroinflammation

Contact Info

Product

Resources

About